Literature DB >> 3726111

Neck neoplasms: MR imaging. Part I. Initial evaluation.

H S Glazer, J H Niemeyer, D M Balfe, V R Devineni, B Emami, R E Hayden, D J Aronberg, R G Levitt, M P Ward, S S Sagel.   

Abstract

Untreated neoplasms of the neck (tumors of the oropharynx, supraglottic area, carotid body, and thyroid, in addition to malignant lymphadenopathy) were evaluated in 23 patients with magnetic resonance (MR) imaging. The results were compared with computed tomographic (CT) scans in 20 patients. Contrast between tumor and fat was best on relatively T1-weighted images (500/30-35 [TR msec/TE msec]), whereas separation of tumor and muscle was best with relatively T2-weighted pulse sequences (1,500/90). Balanced images (1,500/30-35) provided best overall image quality and best demonstrated vascular anatomy. MR imaging was usually superior to CT in showing the relationship of tumor mass to muscle. MR imaging and contrast material-enhanced CT were equivalent in most patients in defining vascular anatomy, but MR imaging was superior when intravenous contrast material was not administered. However, CT was more helpful in showing bone and cartilage anatomy, and in some patients CT also was better in showing airway abnormalities. Despite these limitations, MR imaging is a promising imaging technique for studying neoplasms of the neck.

Entities:  

Mesh:

Year:  1986        PMID: 3726111     DOI: 10.1148/radiology.160.2.3726111

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  3 in total

Review 1.  Dysphagia after laryngeal surgery: radiologic assessment.

Authors:  D M Balfe
Journal:  Dysphagia       Date:  1990       Impact factor: 3.438

2.  The role of different imaging procedures in early diagnosis and management of descending necrotizing mediastinitis.

Authors:  X Yang; S Soimakallio
Journal:  Eur Arch Otorhinolaryngol       Date:  1996       Impact factor: 2.503

Review 3.  Magnetic resonance imaging of head and neck tumors.

Authors:  R B Lufkin; W Hanafee
Journal:  Cancer Metastasis Rev       Date:  1988-04       Impact factor: 9.264

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.